| |
 |
 |
  |
|
|
|
 |
|
|
|
| |
Publications and review articles
B.S. Schug, F. Donath and H.H. Blume
|
| |
Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following i.m. single dose administration in healthy postmenopausal volunteers
Int. Journal of Clinical Pharmacology and Therapeutics, 50 (2): 100-117, 2012
|
Donath F, Braeter M, Feustel C
|
| |
The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patiens
Int J Clin Pharmacol Ther, 2011
|
Blume HH, Brendel E, Brudny-Klöppel M, Grebe S, Lausecker B, Rohde G, Siethoff C
|
| |
Workshop/Conference Report on EMA Draft Guideline on Validation of Bioanalytical Methods
Eur J Pharm Sci, 42: 300-305, 2011
|
Blume HH, Wedemeyer RS
|
| |
Austausch von starken Opioiden? - Die therapiäquivalente Arzneimittelqualität muss gewährleistet sein
Deutsche Apothekerzeitung, 150 (47): 84-89, 2010
|
Ruf P, Kluge M, Jäger M, Burges A, Volvat C, Heiss M, Hess J, Wimberger P, Brandt B, Lindhofer H
|
| |
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
Br J Clin Pharmacol, 69 (6): 617-625, 2010
|
Sabatowski R, Grond S, Blume HH
|
| |
Anforderungen an einer optimierte Opioidtherapie chronischer Schmerzen. Gleichmäßige Plasmaspiegel versus chronoadjustierte Analgesie
MMW-Fortschr. Med. Originalien, 152: 12-15, 2010
|
Blume HH, Wedemeyer RS, Gallwitz B
|
| |
Bedeutung von GLP-1 für die Glucose-Homöostase
PharmUZ, 39: 100-107, 2010
|
Stauss-Grabo M, Warnke A, Atiye S, Wedemeyer R, Blume HH
|
| |
Investigation of the tolerability and safety of film-coated tablets containing ivy extracts (Prospan ® Cough Tablets) in the treatment of colds accompanied by coughing
58th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Products Research, Berlin, 29th August-2nd September, 2010
|
Anschütz M, Wonnemann M, Schug BS, Toal C, Donath F, Pontius A, Pauli K, Brendel E, Blume HH
|
| |
Differences in bioavailability between 60mg of nifedipine osmotic pushpull systems after fasted and fed administration
Int J Clin Pharmacol Ther, 48 (2): 158-170, 2010
|
Blume, H. & Schug, B.
|
| |
Bioavailability/bioequivalence requirements of immediate release products: resolutions and issues
In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (2010) pp. 101-106
|
Grape S, Schug S, Lauer S, Schug BS
|
| |
Fentanyl Formulations for the Management of Pain: A Review
Drugs, 70 (1): 57-72, 2010
|
Kuhn UD, Anschütz M, Schmücker K, Schug BS, Hippius M, Blume HH
|
| |
Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics
Int J Clin Pharmacol Ther, 48 (1): 1-10, 2010
|
Anschutz, M., Garbacz, G., Kosch, O., Donath, F., Wiedmann, J., Hoeckh, W., Trahms, L., Schug, B., Weitschies, W., and Blume, H.
|
| |
Characterization of the behavior of alginate-based microcapsules in vitro and in vivo
Int.J.Clin.Pharmacol.Ther., 47/9 (2009) 556-563
|
Garbacz, G., Adam, U., Schug, B., Blume, H., and Weitschies, W.
|
| |
Nifedipin-Retardtabletten mit unterschiedlicher Galenik
DAZ, 27/ (2009) 3010-3016
|
Weitschies W, Blume HH, Mönnikes H
|
| |
Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastroinestinal tract
Eur J Pharm Biopharm, 74 (1): 93-101, 2010
|
Adam U, Schug BS, Blume HH, Weitschies W
|
| |
Nifedipin-Retardtabletten mit unterschiedlicher Galenik
Deutsche Apothekerzeitung, 149 (27): 3010-3016, 2009
|
Anschütz M, Flochert F, Donath F, Schug BS, Blume HH
|
| |
Characterisation of gastric residence time of Provide Xtra DRINK in healty volunteers
30th ESPEN Congress, Florence, September 13-16, 2009
|
Anschütz M, Garbacz G, Kosch O, Donath F, Wiedmann J, Hoeckh W, Trahms L, Schug BS, Weitschies W, Blume HH
|
| |
Characterization of the behavior of alginate-based microcapsules in vitro and in vivo
Int J Clin Pharmacol Ther, 47 (9): 556-563, 2009
|
Warnke A, Schug BS, Vanderbist F, Blume HH
|
| |
Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources
Int J Clin Pharmacol Ther, 47(6): 405-412, 2009
|
Anschütz M., Flochert F., Schug B., Blume H., Weitschies W.
|
| |
Characterisation of gastric residence time of ProvideXtra DRINK in healthy volunteers
2008
|
Blume H, Ludwig F, Mathis G, Schug B
|
| |
GCP-Standards in klinischen Studien mit Medizinprodukten: Chance oder Hindernis?
Medizinprodukte Journal; 15 (3): 148-155, Okt 2008
|
Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume HH
|
| |
Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight Haparin: Results of a study in healthy subjects with Enoxaparin
J Clin Pharmacol; 48: 1189-1196, 2008
|
Schug B, Blume H
|
| |
Schneller am Ziel mit Magnetic Marker Monitoring
DZKF; 12 (7/8): 51-56, 2008
|
Warnke, A., Schug, B., Vanderbist, F., and Blume, H.
|
| |
Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration
MMW.Fortschr.Med., 150 Suppl 1/ (2008) 36-42
|
Warnke A, Schug B, Vanderbist F, Blume H
|
| |
Bedeutung der Galenik in der "chrono-adjustierten" Schmerzbehandlung.
MMW-Fortschr.Med.Originalien; 150 (I): 36-42, 2008
|
Wonnemann M, Schug BS, Anschütz M, Brendel E, De Nucci G, Blume HH
|
| |
Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study
Clin Ther.; 30 (1):48-58, Jan. 2008
|
Anschütz M, Blume H, Schug B, Weitschies W
|
| |
Gastro-intestinal Transit of Enteric Coated Mesalazine Products: Magnetic Marker Monitoring
CRS 2007 Annual Meeting, Long Beach Convention Center, California, July 7-11, 2007
|
Nassr, N., Lahu, G., von, R.O., Reutter, F., Knoerzer, D., Zech, K., Erb, K.A., Schug, B., Blume, H., and Hermann, R.
|
| |
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects
Br.J.Clin.Pharmacol., 63/3 (2007) 365-370
|
Richert H, Kosch O, Görnert P
|
| |
Magnetic Monitoring as a Diagnostic Method for Investigating Motility in the Human Digestive System
in ´Magnetism in Medicine´, a Handbook, edited by Andrä W and Nowak H, Second Edition, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007
|
Weinmeister S, Donath F, Anschütz M, Folchert F, Schug B
|
| |
Gastrointestinal tolerance of a high-energy oral nutritional supplement (ONS) in healthy elderly and dialysis patients
29th ESPEN Congress on Clinical Nutrition and Metabolism, Prague, September 8-11, 2007
|
Wonnemann M, Helm I, Stauss-Grabo M, Röttger-Luer P, Tran C-T, Canenbley R, Donath F, Nowak H, Schug BS, Blume HH
|
| |
Lidocaine 8 mg Sore Throat Lozenges in the Treatment of Acute Pharyngitis
Arzneimittel-Forschung (Drug Research), 57 (11): 689-697, 2007
|
Blume HH, Anschütz M, Schmücker K, Schug BS, Haueisen J, Weitschies W
|
| |
Gastro-intestinal transit of solid oral dosage forms: Imaging studies using Magnetic Marker Monitoring technique
ACCP 2006 Annual Meeting, America´s Center Convention Center, St. Louis, Missouri, October 26–29, 2006
|
Blume HH, Donath F, Warnke A, Schug BS
|
| |
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors
Drug Safety, 29(9): 769-784, 2006
|
Haberkorn W, Steinhoff U, Burghoff M, Kosch O, Morguet A, Koch H
|
| |
Pseudo current density maps of electrophysiological heart, nerve or brain function and their physical basis
Biomagn Res Technol, 4:5, 13.10.2006
|
Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug BS, Blume HH, Hermann R
|
| |
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects
Br J Clin Pharmacol, 63(3): 365-370, 2006
|
Wonnemann M, Schug BS, Schmücker K, Brendel E, van Zwieten PA, Blume HH
|
| |
Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union
Int J of Clin Pharmacology and Therapeutics, 44(1): 38-48, 2006
|
Blume HH, Schug BS, Tautz J, Erb K
|
| |
Neue Richtlinien für die Beurteilung der Bioverfügbarkeit/ Bioäquivalenz
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2005 48: 548-555, 2005
|
Lehmann G, Folchert F, Schug BS, Anschütz M
|
| |
Charakterisierung der Magenentleerung einer proteinhydrolysathaltigen, kohlenhydratreichen Trinknahrung im Vergleich zu einer kohlenhydratreichen Referenznahrung
Hauptstadtkongress für Anästhesiologie und Intensivmedizin, Berlin 09.06.-11.06.2005
|
Migliorança LH, Barrientos-Astigarraga RE, Schug BS, Blume HH, Pereira AS, De Nucci G
|
| |
Felodipine quantification in human plasma by high performance liquid cromatography coupled to tandem mass spectrometry
Journal of Chromatography B, 814, 217-223, 2005
|
Nassr N, Lahu G, Wolf D, Erb K, Knoerzer D, Zech K, Wurst W, Hermann R.
|
| |
Lack of pharmacokinetic interaction between roflumilast and midazolam
European Journal of Clinical Pharamcology, 61(9): 715, 2005
|
Warnke A, Blume HH
|
| |
Wie die Arzneiform zum Therapieerfolg beiträgt - Arzneizubereitungen mit Calciumkanal-Blockern
Pharmazie in unserer Zeit, 34 (5): 400-410, 2005
|
Wolf D, Folchert F, Blume HH
|
| |
Gastric emptying and gastric residual volume after intake of a sip feed containing carbohydrates and protein hydrolysate
27th Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN), Brussels 27.08. - 30.08.2005
|
Keller JH, Karas M, Müller WE, Volmer DA, Eckert GP, Tawab MA, Blume HH, Dingermann T, Schubert-Zsilavecz M
|
| |
Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry
Anal. Chem. 75(22): 6084-8, 2003
|
Staab A, Schug BS, Larsimont V, Elze M, Thummler D, Mutschler E, Blume HH
|
| |
Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses
Eur J Pharm Sci. 18 (2): 121-8., 2003
|
Blume HH, Wonnemann M, Wolf HT
|
| |
NSAR: Konzepte zur galenischen Optimierung
Pharmazie in unserer Zeit. 31 (2): 170-178, 2002
|
Blume HH, Schug BS, Brendel E
|
| |
Sind Nifedipin-Retardpräparate austauschbar?
Deutsche Apothekerzeitung. 142 (10): 1192-1204, 2002
|
Kressmann S, Müller WE, Blume HH
|
| |
Pharmaceutical quality of different Ginkgo biloba brands
J Pharm Pharmacol. 54(5): 661-9, 2002
|
Chen, X., Zhong, D., Xu, H., Schug, B., and Blume, H.
|
| |
Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma
J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 768/2 (2002) 267-275
|
Kaunzinger, A., Baumeister, A., Cuda, K., Haring, N., Schug, B., Blume, H.H., Raddatz, K., Fischer, G., and Schubert-Zsilavecz, M.
|
| |
Determination of 11-keto-boswellic acid in human plasma
J.Pharm.Biomed.Anal., 28/3-4 (2002) 729-739
|
Kressmann S, Biber A, Wonnemann M, Schug BS, Blume HH, Müller WE
|
| |
Influence of pharmaceutical quality on the bioavailability of active components form Ginkgo biloba preparations
J Pharm Pharmacol. 54 (11): 1507-14, 2002
|
Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH
|
| |
The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast
Br J Clin Pharmacol. 53 (6): 582-8, 2002
|
Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH
|
| |
Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union
Eur J Pharm Sci. 15 (9): 279-285, 2002
|
Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH
|
| |
Dosage form-related food interaction observed in a marketed one-daily nifedipine formulation after a high-fat American breakfast
Eur J Clin Pharmacol. 58 (2): 119-25, 2002
|
Blume HH, Wonnemann M, Wolf HT
|
| |
NSAR: Konzepte zur galenischen Optimierung
Pharmazie in unserer Zeit. 31 (2): 170-178, 2002
|
Blume HH, Schug BS, Brendel E
|
| |
Sind Nifedipin-Retardpräparate austauschbar?
Deutsche Apothekerzeitung. 142 (10): 1192-1204, 2002
|
Blume HH, Cordes H, Klaffenbach P, Schug BS
|
| |
Qualität von Omeprazol-Präparaten
Deutsche Apothekerzeitung. 141(40): 73-78, 2001
|
Chen X, Zhong D, Xu H, Schug BS, Blume HH
|
| |
Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry
J Chromatogr B Biomed Sci Appl. 755 (1-2): 195-202, 2001
|
Schug BS, Wolf D, Nilius R, Martin W, Schall R, Blume HH
|
| |
Product related food effects for nifedipine once daily solid oral dosage forms
Poster at the APV-World Conference. Berlin, 2000
|
Blume HH, Schug BS
|
| |
Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?
Eur J Drug Metab Pharmacokinet. 25 (1): 41-8, 2000
|
Blume HH., Schug BS
|
| |
Qualität von Eisenpräparaten
Deutsche Apothekerzeitung. 139 (7): 47- 50, 1999
|
Blume HH, Schug BS
|
| |
The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
Eur J Pharm Sci. 9 (2), 117-121, 1999
|
Breithaupt-Grogler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, Schug BS, Belz GG
|
| |
Dose-proportionality of oral thioctic acid-coincidence of assessments via pooled plasma and individual data
Eur J Pharm Sci. 8 (1), 57-65, 1999
|
Gleiter CH, Schreeb KH, Freudenthaler S, Thomas M, Elze M, Fieger-Buschges H, Potthast H, Schneider E, Schug BS, Blume HH, Hermann R
|
| |
Lack of interaction between thioctic acid, glibenclamide and acarbose
Br J Clin Pharmacol. 48 (6), 819-25, 1999
|
Heinrich-Nols J, Schug BS, Evers G, Larsimont V, Elze M, Blume HH, Lee LS, Crawford F
|
| |
Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers
Int J Clin Pharmacol Ther. 37 (3), 153-58, 1999
|
Mazur D, Schug BS, Evers G, Larsimont V, Fieger-Büschges H, Gimbel W, Keilbach-Bermann A, Blume HH
|
| |
Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation
Int J Clin Pharmacol Ther. 37 (8), 383-92, 1999
|
Schug, B. and Blume, H.
|
| |
Qualität von Eisenpräparaten - Sind Bioverfügbarkeitsprüfungen erforderlich?
DAZ, 139 (Nr. 7)/ (1999) 719-722
|
Schug BS, Schubert-Zsilavecz M, Blume HH
|
| |
BCS-Wegweiser bei Phytopharmaka
Loew D, Blume HH, Dingermann T (eds.): Phytopharmaka V, Steinkopff Verlag Darmstadt, 35-42, 1999
|
Mazur, D., Schug, B., Elze, M., and Blume, H.
|
| |
Klinische Studien 9
DAZ, 138/ (1998) 3399-3401
|
Mazur, D., Schug, B., Elze, M., and Blume, H.
|
| |
Klinische Studien 10
138/ (1998) 3658-3661
|
Mazur, D., Schug, B., Evers, G., Elze, M., Retzow, A., Wangemann, M., and Blume, H.
|
| |
Trough concentrations as parameter for the autoinduction of carbamazepine during repetitive oral administrations
Naunyn Schmiedebergers Arch Pharmacol, 357 (suppl.)/ (1998)
|
Mazur, D., Schug, B., Elze, M., & Blume, H.
|
| |
Planung, Durchführung und Auswertung klinischer Studien
In Lehrbuch der klinischen Pharmazie, U. Jaehde et al., eds., Wissenschaftliche Verlagsgesellschaft Stuttgart, (1998) pp. 115-137
|
Schug, B., Hermann, R., Blume, H., and Elze, M.
|
| |
Gender effect on the pharmacokinetics of thioctic acid: an evaluation of several bioavailability studies
Naunyn Schmiedebergers Arch Pharmacol, 357 (suppl.)/ (1998)
|
Schug BS
|
| |
Das Biopharmazeutische Klassifizierungssystem BCS - Neuer Ansatz bei der Beurteilung von Arzneimitteln
Deutsche Apotheker Zeitung 138 (23), 45-51, 1998
|
Wangemann, M., Retzow, A., Evers, G., Mazur, D., Schug, B., and Blume, H.
|
| |
Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration
Arzneimittelforschung., 48/12 (1998) 1131-1137
|
Blume, H., Evers, G., Elze, M., Schug, B., and Möhrke, W.
|
| |
Absolute Bioavailability of two oral dantrolene formulations
Naunyn Schmiedebergers Arch Pharmacol, 355/ (1997)
|
Potthast, H., Elze, M., Fieger-Buschges, H., Scheithauer, S., Schug, B., and Blume, H.
|
| |
Relative bioavailability of etilefrine from different galenical formulations
Naunyn Schmiedebergers Arch Pharmacol, 355/ (1997)
|
Schug, B., Schneider, E., Elze, M., Fieger-Buschges, H., Larsimont, V., Popescu, G., Molz, K., Blume, H., and Hermann, R.
|
| |
Study of pharmacokinetic interaction of thioctic acid and metformin
Eur.J.Clin.Pharmacol., 52 (suppl.)/ (1997) 140
|
Schug, B., Ruoff, J., Schäfer, P., Fasold, H., and Blume, H.
|
| |
Vergleichende Untersuchung von FSH-Produkten
PZ, 19/ (1997) 1570-1575
|
Zillig, M., Meier, J., Scheibe, B., Peters, F., Schug, B., and Blume, H.
|
| |
Zur Qualität von Bluttests in Apotheken
PZ (1997) 1666-1671
|
Ali, S., Blume, H., & Schug, B.
|
| |
Sulfonylureas: Physico-chemical properties, analytical methods of determination and bioavailability
In Handbook of Experimental Pharmacology 119, Oral Antidiabetics, J. Kuhlmann & W. Puls, eds., Springer Verlag Berlin, Heidelberg, New York, (1996)
|
Blume, H. & Schug, B.
|
| |
"Bioavailability/ Bioeqivalence requirements of immediate release products: resolutions and issues
In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagai, eds., Business Centre for Academic Societies Japan, (1996) pp. 85-90
|
Blume, H., Schug, B., and Potthast, H.
|
| |
Influence of food on the bioavailability of controlled/modified release products
in: Kuhlmann J, Weihrauch TR (eds.). Eur.J.Clin.Pharmacol., 12/ (1996) 25-32
|
Blume, H., Gundert-Remy, U., Schug, B., Elze, M., and Staab, A.
|
| |
Bioverfügbarkeit von Rytmonorm-Importen
PZ, 141/ (1996) 4475-4489
|
Schneider E., Gleiter Ch., Schug B., Elze M., Hermann R., Gundert-Remy U., Blume H.
|
| |
Influence of food intake on the bioavailability of alpha-lipoic acid.
|
Gleiter, C.H., Schug, B.S., Hermann, R., Elze, M., Blume, H.H., and Gundert-Remy, U.
|
| |
Influence of food intake on the bioavailability of thioctic acid enantiomers
Eur.J.Clin.Pharmacol., 50/6 (1996) 513-514
|
Larsimont, V., Zhong, D., Fieger-Buschges, H., Schug, B., Staab, A., and Blume, H.
|
| |
Enantioselective pharmacokinetics and bioavailability of diprafenone in healthy volunteers
Eur.J.Pharm.Sci., 4 (suppl.)/ (1996) 95
|
Lipka, E., Crison, J., Schug, B., Blume, H., & Amidon, G.
|
| |
Drug interactions in the gastrointestinal tract and their impact on drug absorption and systemic availability: a mechanistic review
In Handbook of experimental pharmacology, Mechanisms of drug interactions, P. D Arcy, J. McElnay, & P. Welling, eds., Springer Verlag Berlin, Heidelberg, New York, (1996) pp. 13-21
|
Schug, B., Fieger-Buschges, H., Elze, M., Schneider, E., Russ, P., Hermann, R., and Blume, H.
|
| |
Single and multiple dose administration of alpha-lipoic acid in a replicate study design
Eur.J.Clin.Pharmacol., 50/ (1996) 553
|
Schug, B., Elze, M., & Blume, H.
|
| |
Bioequivalence of highly variable drugs and drug products: steady state studies
In Bioavailability, Bioequivalence and Pharmacokinetic Studies, K. Midha & T. Nagau, eds., Business Centre for Academic Societies Japan, (1996) pp. 101-106
|
Schug, B.S. and Blume, H.H.
|
| |
Possibilities and limitations on the interpretation of pharmacokinetic interaction studies (drug-drug, drug-food)
Pharm.Unserer Zeit, 25/4 (1996) 195-196
|
Blume, H., Elze, M., Potthast, H., & Schug, B.
|
| |
Practical strategies and design advantages in highly variable drug studies: multiple dose and replicate administration design
In Bio-international 2, Bioavailability, Bioequivalence and Pharmacokinetic Studies, H. Blume & K. Midha, eds., medpharm Scientific Publishers Stuttgart, (1995) pp. 117-122
|
Potthast, H., Schug, B., Elze, M., Schwerdtle, R., and Blume, H.
|
| |
Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state
Pharmazie, 50/1 (1995) 56-60
|
Potthast, H., Schug, B., and Blume, H.
|
| |
Vergleich von Erythromycinestolat und Erythromycinethylsuccinat
Sozialpädiatrie und Kinderärztliche Praxis, 17/ (1995) 284-286
|
Schug, B., Kraemer, J., Amels, M., Elze, M., Fieger-Buschges, H., Potthast, H., & Blume, H.
|
| |
In-vitro und in-vivo-Untersuchungen zu den biopharmazeutischen Eigenschaften zweier Kombinationsanalgetika
In Deutsche Pharmazeutische Gesellschaft.
|
Schug, B.S. and Kalbhen, D.A.
|
| |
Influence of chloroquine and other substances on the collagenolytic activity in human osteoarthritic cartilage in vitro
Arzneimittelforschung., 45/3 (1995) 285-289
|
Blume, H., Zhong, D., Elze, M., Wendt, G., Schug, B., Scheidel, B., Hutt, H., and Hagenlocher, M.
|
| |
Advantages of a steady-state crossover design in assessment of biorquivalence of highly variable drugs: propafenone
Eur.J.Pharm.Sci., 2/ (1994) 385-393
|
Schug, B. and Blume, H.
|
| |
Bio International 1994: Wichtige Ergebnisse
PZ, 139/ (1994) 2800-2806
|
Schug, B.S. and Kalbhen, D.A.
|
| |
Human recombinant interleukin-1 alpha and beta and articular tissue integrity. An in vivo study on hens and rats
Arzneimittelforschung., 42/6 (1992) 880-881
|
Schug, B. and Kalbhen, D.A.
|
| |
Beeinflussung der Aktivität von Kollagenasen durch verschiedene antirheumatische Wirkstoffe
Pharm.Unserer Zeit, 3/ (1991) 118-119
|
|
| |
|
|
|
|
|
|
|
|